Lupin Limited Gains U.S. FDA Approval and Launches Sugammadex Injection
Global pharmaceutical major Lupin Limited announced that it has successfully launched Sugammadex Injection in the United States, following approval from the United States Food and Drug Administration (U.S. FDA). The launch marks a significant milestone for the company in its focus on respiratory and critical care markets.The U.S. FDA granted approval for Abbreviated New Drug Application (ANDA) for Lupin’s Sugammadex Injection. This bioequivalent medication is designed to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide. It has been launched in two forms: a 200 mg/2 mL (100 mg/mL) Single-Dose Vial and a 500 mg/5 mL (100 mg/mL) Single-Dose Vial.
Sugammadex Injection is indicated for use in adults and pediatric patients aged 2 years and older who are undergoing surgery, serving as the bioequivalent to Bridion® Injection of Merck Sharp & Dohme LLC.
Profile of Lupin Limited
Lupin Limited is a pharmaceutical leader with global operations, headquartered in Mumbai, India, and products distributed across more than 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.Lupin maintains a strong position in the U.S. and India, catering to multiple therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce exceeding 26,000 professionals.
Lupin’s commitment to improving patient outcomes is extended through its dedicated subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
Shares of Lupin Limited are creeping up to ₹2421.7 as of 11:22 AM today, advancing by 0.02% in live trading. The stock trades on a volume of 292,052 shares as investors monitor the movement in the pharmaceutical sector.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.